CVS Caremark, Express Scripts, OptumRx: How PBM drug appeals differ

If you've ever sent what felt like a solid prior authorization appeal to a PBM and gotten crickets, or worse, an automatic denial, you already know that not all pharmacy benefit managers play by the same rules. CVS Caremark, Express Scripts, and OptumRx collectively manage pharmacy benefits for the majority of commercially insured Americans, and each has built its own appeal process with its own quirks, timelines, and pressure points. What works for an Express Scripts formulary exception request may fall completely flat with Caremark. Understanding these differences is what separates a patient who gets their medication from one who doesn't.

Why PBMs don't all think alike

PBMs aren't passive claims processors. They operate under contracts with health plan sponsors — employers, unions, government programs — and those contracts determine which drugs get covered, what step therapy looks like, and how much latitude a reviewer actually has when reading your appeal.

OptumRx is deeply integrated with UnitedHealth Group's clinical infrastructure, so formulary decisions tend to align tightly with UnitedHealthcare's medical policy. Express Scripts, now operating under Evernorth as Cigna's health services arm, has historically taken a formulary-first approach with significant rebate-driven exclusion lists. CVS Caremark occupies a different position because of its vertical integration: it owns retail pharmacies, specialty pharmacies, and a health insurer in Aetna. That creates real conflicts of interest, but also specific leverage points for a well-placed appeal.

Knowing who you're dealing with shapes how you argue a case.

CVS Caremark: documentation depth is your friend

Caremark's appeal process rewards thoroughness. Clinical reviewers are accustomed to detailed medical rationale, and a two-paragraph appeal rarely moves the needle for a specialty drug.

A few things worth knowing:

• Step therapy disputes are common. Caremark frequently requires trials of preferred formulary alternatives before approving a branded agent, even when the prescriber has strong clinical reasoning for bypassing that sequence.


• The formulary exception pathway is separate from the prior authorization appeal. Many billing teams treat these as the same thing. A formulary exception argues that the plan's preferred drug is medically inappropriate for this patient; a PA appeal challenges a denied authorization. Knowing which one applies matters.


• Clinical notes, not just opinions, drive decisions. Reviewers want documented evidence of previous treatment failures, contraindications, or specific clinical indicators. Pull the actual chart notes, lab values, and relevant history.

One practical note: Caremark's online portal forms often have character limits that will truncate a detailed clinical narrative. Always attach a separate clinical summary document rather than relying on the portal text fields alone.

Express Scripts: know the formulary exclusion list cold

Express Scripts maintains one of the most aggressive drug exclusion lists in the industry. Each year, more branded drugs are removed from coverage in favor of biosimilars or competing generics, and January 1 formulary changes catch plenty of practices off guard.

For appeals, the first thing to determine is what actually drove the denial:

• A formulary exclusion (often non-appealable without a true formulary exception pathway)


• A clinical criteria denial (absolutely appealable with proper documentation)


• A quantity limit or duration-of-therapy issue (frequently winnable with the right supporting data)

Express Scripts tends to be more rigid on formulary exclusions than the other two. If a drug is excluded, you're generally working through a formulary exception process that requires documented evidence the patient tried and failed on, or has a contraindication to, the preferred alternative. "The patient prefers this medication" goes nowhere. "Patient developed [specific adverse event] on [preferred alternative] documented on [date]" is the kind of language that actually works.

Their peer-to-peer review process is worth pursuing when you can get it. A prescriber willing to spend 20 minutes on a call with an Express Scripts clinical pharmacist will see approvals at a higher rate than written appeals alone. Flag this option for your providers.

OptumRx: use the UnitedHealth clinical framework

OptumRx appeals have a specific strategic angle available that the other two don't offer as cleanly: alignment with UnitedHealthcare's published clinical policies. Because of the integration between OptumRx and UHC, criteria documents are often publicly available and detailed. If you're appealing a clinical criteria denial, finding the exact policy cited in the denial and then building your appeal around the specific language in that policy is genuinely effective.

A few things that work well:

• Reference specific clinical guidelines (ACC, ADA, ASCO, and similar) that support the prescribed therapy. Reviewers respond to evidence-based frameworks.


• Confirm specialty pharmacy routing before escalating. OptumRx has a preferred specialty pharmacy network, and sometimes a denial is partly logistical. Sorting out routing early can save a full appeal cycle.


• Expedited appeal timelines are real. For oncology, transplant medications, and acute psychiatric conditions, OptumRx does process expedited appeals within 24 to 72 hours. Request expedited review explicitly and document the clinical urgency clearly.

One field observation: OptumRx's online provider portal has improved, but fax-based appeal submissions still work and sometimes process faster. It's worth knowing.

Building an appeal that holds up across all three

The PBM-specific differences matter, but certain fundamentals strengthen appeals regardless of who's reviewing them. They're consistently missed even by experienced billing teams:

• Match your clinical argument to the specific denial reason cited. A generic appeal that doesn't address the actual criteria is easy to deny again.


• Put the prescriber's NPI, the patient's member ID, the drug name and strength, and the original denial reference number on every page. Lost paperwork is a real and common problem.


• Document failure of alternatives with dates, doses, duration, and outcomes, not just "patient tried X."


• Write clearly enough for a non-specialist to follow the logic, but include the clinical specifics that will matter if the case gets escalated. First-level reviewers often don't have clinical training.

AI-powered appeal generators are showing up in more RCM workflows, and for high-volume practices managing appeals across multiple PBMs, they're worth evaluating. They can pull in appropriate clinical language and structure arguments more consistently than building each appeal from scratch. They're tools, not a substitute for knowing the underlying criteria.

Getting smarter about PBM appeals in 2026

PBMs are adding prior authorization requirements, expanding formulary exclusions, and tightening clinical criteria. What cleared in 2024 may require substantially more documentation now.

The practices that manage this well share one habit: they track denial reasons systematically by PBM, not just aggregate outcomes. That means knowing which drugs are being denied repeatedly at one PBM but not others, which criteria language keeps showing up, and which providers' documentation needs work before submission.

Start by pulling your last 90 days of pharmacy denials and sorting by PBM. The patterns will be obvious, and they'll tell you exactly where to focus your time.

---

Tags: pharmacy, PBM, Caremark, Express Scripts, OptumRx, appeals